Tear Biomarkers and Alzheimer's Disease

Area of Science:

• Neuroscience
• Ophthalmology
• Biomarker Discovery

Background:

• Alzheimer's disease (AD) is a common, progressive neurodegenerative disorder causing dementia, presenting diagnostic challenges.
• Current AD diagnosis relies on methods like MRI, PET scans, and cerebrospinal fluid analysis for amyloid-β and tau.
• Effective AD therapies are lacking, emphasizing the need for early detection and monitoring.

Purpose of the Study:

• To investigate the potential of tears as a source for Alzheimer's disease (AD) biomarkers.
• To explore the feasibility of developing non-invasive methods for AD screening and diagnosis using tear biomarkers.

Main Methods:

• Review of existing literature on AD biomarkers and the eye-brain connection.
• Exploration of the potential for tear analysis in identifying AD-specific molecules.
• Assessment of current limitations and future research needs for tear-based AD diagnostics.

Main Results:

• The eye-brain axis suggests tears may contain biomarkers relevant to AD.
• Studies on tear biomarkers for AD are currently limited.
• Existing AD biomarkers include imaging techniques and cerebrospinal fluid analytes.

Conclusions:

• Tears represent a promising, yet understudied, source for AD biomarkers.
• Developing non-invasive tear-based diagnostics could revolutionize AD screening and monitoring.
• Larger-scale studies are essential to validate tears as a reliable diagnostic tool for AD.